Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study

INTRODUCTION: To assess the efficacy and safety of the subcutaneous (s.c.) secukinumab 150 mg with loading (150 mg) or without loading (150 mg no-load) regimen through 104 weeks in patients with active psoriatic arthritis (PsA) in the FUTURE 4 (NCT02294227) study. METHODS: Patients with PsA (N = 341...

Descripción completa

Detalles Bibliográficos
Autores principales: Kivitz, Alan J., Nash, Peter, Tahir, Hasan, Everding, Andrea, Mann, Heřman, Kaszuba, Andrzej, Pellet, Pascale, Widmer, Albert, Pricop, Luminita, Abrams, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702584/
https://www.ncbi.nlm.nih.gov/pubmed/31228101
http://dx.doi.org/10.1007/s40744-019-0163-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702584/
https://www.ncbi.nlm.nih.gov/pubmed/31228101
http://dx.doi.org/10.1007/s40744-019-0163-5

Ejemplares similares